{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:43:50Z","timestamp":1781189030449,"version":"3.54.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Recent advances in molecular diagnostic technologies allow for the evaluation of solid tumor malignancies through noninvasive blood sampling, including circulating tumor DNA profiling (ctDNA). Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, often because of late presentation of disease. Diagnosis is often made using endoscopic ultrasound or endoscopic retrograde cholangiopancreatography, which often does not yield enough tissue for next-generation sequencing. With this study, we sought to characterize the ctDNA genomic alteration landscape in patients with advanced PDAC with a focus on actionable findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>From December 2014 through October 2019, 357 samples collected from 282 patients with PDAC at Mayo Clinic underwent ctDNA testing using a clinically available assay. The majority of samples were tested using the 73-gene panel which includes somatic genomic targets, including complete or critical exon coverage in 30 and 40 genes, respectively, and in some, amplifications, fusions, and indels. Clinical data and outcome variables were available for 165 patients; with 104 patients at initial presentation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients included in this study had locally advanced or metastatic PDAC. Samples having at least one alteration, when variants of unknown significance (VUS) were excluded, numbered 266 (75%). After excluding VUS, therapeutically relevant alterations were observed in 170 (48%) of the total 357 cohort, including KRAS (G12C), EGFR, ATM, MYC, BRCA, PIK3CA, and BRAF mutations. KRAS, SMAD, CCND2, or TP53 alterations were seen in higher frequency in patients with advanced disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study is the largest cohort to date that demonstrates the feasibility of ctDNA testing in PDAC. We provide a benchmark landscape upon which the field can continue to grow. Future applications may include use of ctDNA to guide treatment and serial monitoring of ctDNA during disease course to identify novel therapeutic targets for improved prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis often due to late presentation of disease. Biopsy tissue sampling is invasive and samples are often inadequate, requiring repeated invasive procedures and delays in treatment. Noninvasive methods to identify PDAC early in its course may improve prognosis in PDAC. Using ctDNA, targetable genes can be identified and used for treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13717","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T15:57:58Z","timestamp":1612799878000},"page":"569-578","source":"Crossref","is-referenced-by-count":37,"title":["Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma"],"prefix":"10.1093","volume":"26","author":[{"given":"Gehan","family":"Botrus","sequence":"first","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kosirorek","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Kusne","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Junior","given":"Pedro Luiz Serrano","family":"Uson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, College of Medicine and Oncology, University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leylah M.","family":"Drusbosky","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Dada","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phani Keerthi","family":"Surapaneni","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Starr","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashton","family":"Ritter","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"McMillan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Wylie","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mody","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"2022020214224915000_onco13717-bib-0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022020214224915000_onco13717-bib-0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/SLA.0b013e31825ffbfb","article-title":"Screening for pancreatic cancer: Why, how, and who?","volume":"257","author":"Poruk","year":"2013","journal-title":"Ann Surg"},{"key":"2022020214224915000_onco13717-bib-0003","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","article-title":"Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer","volume":"18","author":"Wei","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2022020214224915000_onco13717-bib-0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2022020214224915000_onco13717-bib-0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br J Cancer"},{"key":"2022020214224915000_onco13717-bib-0006","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cancers9010005","article-title":"Circulating nucleosomes and nucleosome modifications as biomarkers in cancer","volume":"9","author":"McAnena","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2022020214224915000_onco13717-bib-0008","doi-asserted-by":"crossref","first-page":"492","DOI":"10.21037\/tlcr.2016.10.03","article-title":"Methylation analyses in liquid biopsy","volume":"5","author":"Lissa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jgg.2017.11.006","article-title":"Genetic profiling of cancer with circulating tumor DNA analysis","volume":"45","author":"Lu","year":"2018","journal-title":"J Genet Genomics"},{"key":"2022020214224915000_onco13717-bib-0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fmolb.2015.00013","article-title":"Methylation of cell-free circulating DNA in the diagnosis of cancer","volume":"2","author":"Warton","year":"2015","journal-title":"Front Mol Biosci"},{"key":"2022020214224915000_onco13717-bib-0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"2022020214224915000_onco13717-bib-0012","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): A phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022020214224915000_onco13717-bib-0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nat Med"},{"key":"2022020214224915000_onco13717-bib-0014","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/cells8101251","article-title":"Translational application of circulating DNA in oncology: Review of the last decades achievements","volume":"8","author":"Tuaeva","year":"2019","journal-title":"Cells"},{"key":"2022020214224915000_onco13717-bib-0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1542-3565(04)00013-8","article-title":"Clinical and genetic characteristics of hereditary pancreatitis in Europe","volume":"2","author":"Howes","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022020214224915000_onco13717-bib-0016","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022020214224915000_onco13717-bib-0017","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2022020214224915000_onco13717-bib-0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"2022020214224915000_onco13717-bib-0019","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0020","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0021","article-title":"OncoKB: A precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2022020214224915000_onco13717-bib-0022","doi-asserted-by":"crossref","first-page":"JCO1800328","DOI":"10.1200\/JCO.18.00328","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing","volume":"36","author":"Slavin","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022020214224915000_onco13717-bib-0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cancergen.2017.08.006","article-title":"Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer","volume":"218\u2013219","author":"Vietsch","year":"2017","journal-title":"Cancer Genet"},{"key":"2022020214224915000_onco13717-bib-0024","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1158\/0008-5472.CAN-07-0874","article-title":"Zonal heterogeneity for gene expression in human pancreatic carcinoma","volume":"67","author":"Nakamura","year":"2007","journal-title":"Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0025","first-page":"835","article-title":"Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer","volume":"62","author":"Harada","year":"2002","journal-title":"Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0026","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Cancer Genome Atlas Research Network; Cancer Genome Atlas Research","year":"2017","journal-title":"Cancer Cell"},{"key":"2022020214224915000_onco13717-bib-0027","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","article-title":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","volume":"156","author":"Bernard","year":"2019","journal-title":"Gastroenterology"},{"key":"2022020214224915000_onco13717-bib-0028","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/annonc\/mdx004","article-title":"High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients","volume":"28","author":"Allenson","year":"2017","journal-title":"Ann Oncol"},{"key":"2022020214224915000_onco13717-bib-0029","doi-asserted-by":"crossref","first-page":"87221","DOI":"10.18632\/oncotarget.20250","article-title":"Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer","volume":"8","author":"Adamo","year":"2017","journal-title":"Oncotarget"},{"key":"2022020214224915000_onco13717-bib-0030","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1038\/s41598-019-47489-7","article-title":"Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in pancreatic cancer","volume":"9","author":"Mohan","year":"2019","journal-title":"Sci Rep"},{"key":"2022020214224915000_onco13717-bib-0031","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","article-title":"Mutant KRAS Circulating tumor DNA is an accurate tool for pancreatic cancer monitoring","volume":"23","author":"Perets","year":"2018","journal-title":"The Oncologist"},{"key":"2022020214224915000_onco13717-bib-0032","doi-asserted-by":"crossref","first-page":"18425","DOI":"10.1038\/srep18425","article-title":"Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer","volume":"5","author":"Takai","year":"2015","journal-title":"Sci Rep"},{"key":"2022020214224915000_onco13717-bib-0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2022020214224915000_onco13717-bib-0034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"2022020214224915000_onco13717-bib-0035","doi-asserted-by":"crossref","first-page":"97769","DOI":"10.18632\/oncotarget.22080","article-title":"Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"2022020214224915000_onco13717-bib-0036","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1038\/s41598-017-08297-z","article-title":"Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer","volume":"7","author":"Del Re","year":"2017","journal-title":"Sci Rep"},{"key":"2022020214224915000_onco13717-bib-0037","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","article-title":"Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer","volume":"29","author":"Kruger","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020214224915000_onco13717-bib-0038","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.molonc.2015.11.012","article-title":"Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer","volume":"10","author":"Tjensvoll","year":"2016","journal-title":"Mol Oncol"},{"key":"2022020214224915000_onco13717-bib-0039","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cas.14245","article-title":"Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy","volume":"111","author":"Sugimori","year":"2020","journal-title":"Cancer Sci"},{"key":"2022020214224915000_onco13717-bib-0040","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020214224915000_onco13717-bib-0041","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022020214224915000_onco13717-bib-0042","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13053-020-00148-9","article-title":"Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer","volume":"18","author":"Macklin-Mantia","year":"2020","journal-title":"Hered Cancer Clin Pract"},{"key":"2022020214224915000_onco13717-bib-0043","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022020214224915000_onco13717-bib-0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2020.00023","article-title":"Circulating tumor DNA-based detection of microsatellite instability and response to immunotherapy in pancreatic cancer","volume":"11","author":"Kamatham","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13717","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/569\/42367504\/oncolo_26_7_569.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/569\/42367504\/oncolo_26_7_569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T14:28:50Z","timestamp":1643812130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/569\/6510487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,5]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13717","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,3,5]]}}}